

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 July 2001 (26.07.2001)

PCT

(10) International Publication Number
WO 01/53278 A1

(51) International Patent Classification: **C07D 265/24**,
A61P 3/04, A61K 31/536

Alizyme Therapeutics Limited, Granta Park, Great Abingdon, Cambridge CS1 6GS (GB).

(21) International Application Number: PCT/GB01/00171

(74) Agents: FLORENCE, Julia, Anne et al.; Kilburn & Strode, 20 Red Lion Street, London WC1R 4PJ (GB).

(22) International Filing Date: 17 January 2001 (17.01.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0001572.7 24 January 2000 (24.01.2000) GB

(71) Applicant (for all designated States except US): ALIZYME THERAPEUTICS LIMITED [GB/GB]; Granta Park, Great Abingdon, Cambridgeshire CB1 6GS (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (for US only): DOWNHAM, Robert [GB/GB]; Cambridge Discovery Chemistry, The Merrifield Centre, Rosemary Lane, Cambridge CB1 3LQ (GB). PALMER, Richard, Michael, John [GB/GB]; Alizyme Therapeutics Limited, Granta Park, Great Abingdon, Cambridge CS1 6GS (GB). HODSON, Harold, Francis [GB/GB]; 69 Whitecroft Way, Beckenham, Kent BR3 3AW (GB). DUNK, Christopher, Robert [GB/GB];

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 2-THIO-4H-3,1-BENZOXAZIN-4-ONE DERIVATIVES FOR USE AS ENZYME INHIBITORS



(57) Abstract: The use of a compound, comprising formula (I) or a salt, ester, amide or prodrug thereof in the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality e.g. in the control and inhibition of unwanted enzymes in products and processes. The compounds are also useful in medicine e.g. in the treatment of obesity and related conditions. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them. In formula (I) A is an optionally substituted 6-membered aromatic or heteroaromatic ring; and R¹ is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cy-

cloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups.

WO 01/53278 A1

2-THIO-4H-3,1-BENZOXAZIN-4-ONE DERIVATIVES FOR USE AS ENZYME INHIBITORS

The present invention provides benzoxazinone compounds, their use in the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality, their use in medicine, and particularly in the prevention and/or treatment of obesity or an obesity-related disorder. Also provided are methods for the prevention and/or treatment of obesity or an obesity-related disorder and for promoting/aiding non-medical weight loss and the use of the compounds in the manufacture of a medicament for the aforementioned indications. The invention also provides processes for manufacture of said compounds, compositions containing them and methods for manufacturing such compositions.

In the last 20 years, there has been an increasing trend in obesity in the populations of the developed world. The increased incidence of obesity is due in part to the ready availability of food in numerous retail outlets and westernised diets that have high saturated fat and lower fibre contents such that the food is energy dense. The lifestyle of the populations of the developed world has also become more sedentary with the increased mechanisation of society and the steady reduction of manual labour intensive industries. There now exists an energy imbalance between the energy intake from calorie dense foods and the reduced energy expenditure required for a sedentary lifestyle. Some of the excess energy intake is stored as fat in the adipose tissue, the accumulation of which over a period of time results in obesity and can be a significant contributory factor to other disease and disorders.

Obesity is now recognised by the medical profession as a metabolic disease. In the USA, it is estimated that 25% of the adult population is considered clinically obese (Body Mass Index > 30). Obesity can be a debilitating condition which reduces the quality of life and increases the risk of related disorders such as diabetes, cardiovascular disease and hypertension. It has been estimated that \$45 billion of US healthcare costs, or 8% per annum of total healthcare spend, is as a direct result of

obesity. The traditional approaches to long term weight management such as diet and exercise have proved ineffective alone to control the spread of obesity. Today, more than ever, there is considerable interest in developing safe, effective drugs for the treatment of obesity.

5

Pharmacological approaches to the treatment of obesity have focused on either developing drugs that increase energy expenditure or drugs that reduce energy intake. One approach to the reduction of energy intake is to reduce the body's ability to digest and absorb food, in particular fat. The key enzymes involved in the digestion of fat are hydrolytic enzymes. The most significant of the fat degrading enzymes are lipases, primarily, but not exclusively pancreatic lipase that is secreted by the pancreas into the gut lumen. The lipase inhibitor lipstatin has formed the basis of the anti-obesity drug, orlistat. European Patent Application No. EP129748, relates to Orlistat and related compounds and their use in inhibiting pancreatic lipase and treating hyperlipaemia and obesity.


15

Even if orlistat provides an effective method for treating obesity, there remains a need to provide alternative drugs and methods for use in the control and treatment of obesity and obesity-related disorders and in promoting or aiding non-medical weight loss. Inhibitors of enzymes involved in the degradation of fat are provided here and shown to be effective in the prevention and/or treatment of obesity, obesity-related disease and/or in promoting cosmetic weight loss.

20

Krantz *et al.*, *J. Med. Chem.*, 1990, 33(2);464-469 describes benzoxazinones of formula

25



30.


wherein R^2 is *inter alia* MeS-, EtS-, iPrS-, BnS-, -SCH₂COOEt, -SCH₂CH=CHPh, 3-indolyl-CH₂S- and 4-ind-CH₂S-; R^5 is variously hydrogen, methyl or ethyl; R^6 is variously hydrogen, methyl, methoxy, HNAC or NMe₂; R^7 is variously hydrogen, ethyl or methoxy or R^6 and R^7 together represent a group -CH=CH-CH=CH-; and R^8 is variously hydrogen or methyl. The compounds are said to be inhibitors of human leukocyte elastase.

International application numbers PCT/GB00/00032 and PCT/GB00/00031 relate to 2-oxy and 2-amino benzoxazinone compounds. These applications provide alternative methods for use in the control and treatment of obesity and obesity-related disorders.

We have now found that a particular class of benzoxazinone compounds has activity as lipase inhibitors.

Accordingly, in a first aspect, the present invention provides the use of a compound of formula (I):

20



(I)

or a pharmaceutically acceptable salt, ester, amide or prodrug thereof;
 in the manufacture of a medicament for the treatment of conditions requiring the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality;
 wherein in formula (I):

A is a 6-membered aromatic or heteroaromatic ring optionally substituted with one or more groups as defined below for R¹; and

- 5 R¹ is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups, wherein the substituents are one or more independently of halogen, alkyl,
 10 halosubstituted alkyl, aryl, arylalkyl, heteroaryl, reduced heteroaryl, reduced heteroarylalkyl, arylalkoxy, cyano, nitro, -C(O)R⁴, -CO₂R⁵, -SOR⁴, -SO₂R⁴, -NR⁶R⁷, -OR⁶, -SR⁶, -C(O)CX¹X²NR⁶R⁷, -C(O)N(OH)R⁶, -C(O)NR⁵R⁴, -NR⁶C(O)R⁴, -CR⁶(NH₂)CO₂R⁶, -NHCX¹X²CO₂R⁶, -N(OH)C(O)NR⁶R⁷, -N(OH)C(O)R⁴, -NHC(O)NR⁶R⁷, -C(O)NHN⁶R⁷, -C(O)N(OR⁵)R⁶, or a lipid or steroid (natural or
 15 synthetic) with the proviso that any hetero atom substituent in R¹ must be separated from the exocyclic sulphur atom by at least two carbon atoms (preferably saturated);

and where:-

- 20 R⁴ is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, reduced heteroaryl, reduced heteroarylalkyl, -OR⁶, -NHCX¹X²CO₂R⁶ or -NR⁶R⁷;

- R⁵ is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl
 25 heteroaryl, heteroarylalkyl, reduced heteroaryl or reduced heteroarylalkyl; and

R⁶ and R⁷ are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, reduced heteroaryl, reduced heteroarylalkyl

5.

or $-(CH_2)_n(OR^5)_m$ wherein n is 1 to 12, preferably 2 to 10, wherein m is 1-3 and R^5 is most preferably C_2-C_{10} alkyl; and

5 X^1 and X^2 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, reduced heteroaryl or reduced heteroarylalkyl.

10 In compounds of formula (I) any alkyl, alkenyl and alkynyl groups and moieties may be straight chain (unbranched) or branched chain. Straight chain alkyl, alkenyl and alkynyl groups or moieties may contain from 1 to 30 carbon atoms, eg. 1 to 25 carbon atoms, preferably 1 to 20 carbon atoms. Branched chain alkyl, alkenyl and alkynyl groups or moieties may contain from 1 to 50 carbon atoms, preferably 1 to 30 carbon atoms. It will be appreciated that alkenyl and alkynyl groups or moieties will contain at least 2 carbon atoms.

15

Preferred values for R^1 , R^4 , R^5 , R^6 , R^7 , X^1 and X^2 are as defined below for formulae (II).

20 In this text, 'reduced', in the context of 'reduced heteroaryl' and the like means fully or partially saturated.

25 Aryl groups include for example optionally substituted unsaturated monocyclic or bicyclic rings of up to 12 carbon atoms, such as phenyl and naphthyl, and partially saturated bicyclic rings such as tetrahydro-naphthyl. Examples of substituents which may be present on an aryl group include one or more of halogen, amino, nitro, alkyl, haloalkyl, alkoxy, phenoxy and phenoxy substituted by one or more of halo, alkyl or alkoxy.


A heteroaryl group or moiety may be for example an optionally substituted 5- or 6-membered heterocyclic aromatic ring which may contain from 1 to 4 heteroatoms selected from O, N and S. The heterocyclic ring may optionally be fused to a phenyl ring. Examples of heteroaryl groups thus include furyl, thienyl, pyrrolyl, oxazolyl, oxazinyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl, triazolyl, triazinyl, pyridazyl, pyrimidinyl, pyrazolyl, indolyl, indazolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzoxazinyl, quinoxalyl, quinolinyl, quinazolinyl, cinnolinyl, benzothiazolyl, pyridopyrrolyl. Suitable substituents include one or more of halogen, oxo, amino, nitro, alkyl, haloalkyl, alkoxy, phenoxy and phenoxy substituted by one or more of halo, alkyl, haloalkyl or alkoxy.

A reduced heteroaryl group or moiety may be for example a fully or partially saturated derivative of the aforementioned heteroaryl groups. Examples of reduced heteroaryl groups thus include pyrrolidinyl, tetrahydrofuryl, tetrahydrothienyl and piperidinyl.

The compounds of formula (I) are used in the manufacture of a medicament for the treatment of conditions requiring the inhibition of an enzyme whose preferred mode of action in vivo is to catalyse the hydrolysis of an ester functionality. Such enzymes include lipases, esterases and phosphoesterases.

The compounds of formula (I) are useful inhibitors of enzymes involved in the degradation of fats. Preferably therefore the first aspect of the invention provides the use of a compound of formula (I) as defined hereinabove, or a pharmaceutically acceptable salt, ester, amide or prodrug thereof, in the manufacture of a medicament for the control or treatment of obesity, or obesity-related disorders or for promoting non-medical weight loss.

Preferably, a compound for use according to the first aspect of the invention is a compound of formula (II):



or a pharmaceutically acceptable salt, ester, amide or prodrug thereof,

10 wherein:-

$R^1, R^4, R^5, R^6, R^7, X^1$ and X^2 are as defined above for formula (I); and

15 R^8, R^9, R^{10}, R^{11} are each independently hydrogen, halo, hydroxy, amino, nitro, cyano,

or a group R^1 , as defined above,

20 or a group $R^{12}Q$ where Q is O, CO, CONH, NHCO, S, SO, SO_2 , or SO_2NH_2 and R^{12} is hydrogen or a group R^1 as defined above,

or a group R^1R^2N where R^1 is as defined above and R^2 is hydrogen or R^1 , with the proviso that any hetero atom substituent in R^1 and/or R^2 must be separated from the nitrogen atom substituent by at least two carbon atoms (preferably saturated).

25

More preferably, a compound for use according to the first aspect of the invention comprises a compound of formula (II), or a pharmaceutically acceptable salt, ester, amide or prodrug thereof; wherein:

- 5 R^1 is either a branched or unbranched alkyl group having up to 25, e.g. up to 20 carbon atoms, an aryl (e.g. optionally substituted phenyl or 2-naphthyl), an arylalkyl group wherein the alkyl moiety has up to 25, e.g. up to 20 carbon atoms, or an arylaryl group, wherein the arylalkyl group or the arylaryl group may be separated by a spacer, and where the spacer can be one or more of an ester, amide, O, CH_2 or
10 a ketone and wherein any aryl group is preferably a phenyl, optionally substituted with alkyl, haloalkyl or halogen;

R^8 is hydrogen or fluorine;

- 15 R^9 is lower branched or unbranched alkyl having 1 to 10 carbon atoms, preferably methyl; cyclic alkyl having 3 to 10 carbon atoms, preferably cyclopropyl; haloalkyl, preferably trifluoromethyl; or a halogen, most preferably chlorine or fluorine;

- 20 R^{10} is hydrogen; lower branched or unbranched alkyl having 1 to 10 carbon atoms, preferably methyl; cyclic alkyl having 3 to 10 carbon atoms, preferably cyclopropyl; haloalkyl, preferably trifluoromethyl; or a halogen, most preferably chlorine or fluorine;

- 25 R^{11} is hydrogen; lower branched or unbranched alkyl having 1 to 10 carbon atoms, preferably methyl; or halogen, preferably fluorine.


In particular, R¹ is an unbranched alkyl group, having 12, 14, 15, 16, 17 or 18 carbon atoms in the alkyl chain. In addition to this particular option for R¹, R⁹ may be methyl.

- 5 In a second aspect, the present invention provides novel compounds of formulae (I) or (II) as defined hereinabove, and pharmaceutically acceptable salts, esters, amides and prodrugs thereof, with the proviso that the following compounds are excluded:

	R ¹	R ⁸	R ⁹	R ¹⁰	R ¹¹
10	Me	H	H	H	H
	Me	Me	H	H	H
	Et	H	H	H	H
	Et	Me	H	H	H
	Et	Et	H	H	H
15	Et	H	Me	H	H
	Et	H	HNAC	H	H
	Et	H	OMe	OMe	H
	Et	H	NMe ₂	H	H
	Et	H	H	Et	H
20	Et	H	H	H	Me
	Et	H	-CH=CH-CH=CH-		H
	iPr	H	H	H	H
	Bn	H	H	H	H
	Bn	H	H	H	Me
25	Bn	H	OMe	OMe	H
	Bn	H	-CH=CH-CH=CH-		H
	CH ₂ COOEt	H	H	H	H
	CH ₂ CH=CHPh	H	OMe	OMe	H
	3-indolylCH ₂	H	OMe	OMe	H
30	4-imdCH ₂	H	OMe	OMe	H

In a preferred feature of the second aspect, the present invention provides novel compounds of formula (Ia):

5



(Ia)

10 or a pharmaceutically acceptable salt, ester, amide or prodrug thereof;
wherein in formula (Ia):

A is an optionally substituted 6-membered aromatic or heteroaromatic ring; and

15 R¹ is a branched C₄₋₅₀alkyl or unbranched C₃₋₂₅alkyl (with the alkyl group optionally interrupted by one or more oxygen atoms), C₂₋₂₅alkenyl, C₂₋₂₅alkynyl, C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkenyl, aryl, arylC₂₋₂₅alkyl, reduced arylC₁₋₂₅alkyl, arylC₂₋₂₅alkenyl, heteroaryl, heteroarylC₂₋₂₅alkyl, heteroarylC₂₋₂₅alkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylC₂₋₂₅alkyl or a substituted derivative of any of the
20 foregoing groups, wherein the substituents are one or more independently of halogen, alkyl, halosubstituted alkyl, aryl, arylalkyl, heteroaryl, reduced heteroaryl, reduced heteroarylalkyl, arylalkoxy, cyano, nitro, -C(O)R⁴, -CO₂R⁵, -SOR⁴, -SO₂R⁴, -NR⁶R⁷, -OR⁶, -SR⁶, -C(O)CX¹X²NR⁶R⁷, -C(O)N(OH)R⁶, -C(O)NR⁵R⁴, -NR⁶C(O)R⁴, -CR⁶(NH₂)CO₂R⁶, -NHCX¹X²CO₂R⁶, -N(OH)C(O)NR⁶R⁷, -N(OH)C(O)R⁴, -
25 NHC(O)NR⁶R⁷, -C(O)NHNHNR⁶R⁷, -C(O)N(OR⁵)R⁶, or a lipid or steroid (natural or synthetic) with the proviso that any hetero atom substituent in R¹ must be separated from the exocyclic sulphur atom by at least two carbon atoms (preferably saturated);

and where:-

R^4 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, reduced heteroaryl, reduced heteroarylalkyl, $-OR^6$, $-NHCX^1X^2CO_2R^6$ or $-NR^6R^7$;

5

R^5 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, reduced heteroaryl or reduced heteroarylalkyl; and

10

R^6 and R^7 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, reduced heteroaryl, reduced heteroarylalkyl or $-(CH_2)_n(OR^5)_m$ wherein n is 1 to 12, preferably 2 to 10, wherein m is 1-3 and R^5 is most preferably C_2-C_{10} alkyl; and

15

X^1 and X^2 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, reduced heteroaryl or reduced heteroarylalkyl.

20

with the proviso that when A is phenyl disubstituted at the 6 and 7 positions with methoxy groups, R^1 is not $CH_2CH=CHPh$.

25

In compounds of formula (Ia) any alkyl, alkenyl and alkynyl groups and moieties may be straight chain (unbranched) or branched chain. Straight chain alkyl, alkenyl and alkynyl groups or moieties may contain from 1 to 30 carbon atoms, eg. 1 to 25 carbon atoms, preferably 1 to 20 carbon atoms. Branched chain alkyl, alkenyl and alkynyl groups or moieties may contain from 1 to 50 carbon atoms, preferably 1 to 30 carbon atoms. It will be appreciated that alkenyl and alkynyl groups or moieties will contain at least 2 carbon atoms.

Preferred values for R¹, R⁴, R⁵, R⁶, R⁷, X¹ and X² are as defined below for formulae (IIa).

5 In this text, 'reduced', in the context of 'reduced heteroaryl' and the like means fully or partially saturated.

Aryl groups include for example optionally substituted unsaturated monocyclic or bicyclic rings of up to 12 carbon atoms, such as phenyl and naphthyl, and partially saturated bicyclic rings such as tetrahydro-naphthyl. Examples of substituents which
10 may be present on an aryl group include one or more of halogen, amino, nitro, alkyl, haloalkyl, alkoxy, phenoxy and phenoxy substituted by one or more of halo, alkyl or alkoxy.

A heteroaryl group or moiety may be for example an optionally substituted 5- or 6-
15 membered heterocyclic aromatic ring which may contain from 1 to 4 heteroatoms selected from O, N and S. The heterocyclic ring may optionally be fused to a phenyl ring. Examples of heteroaryl groups thus include furyl, thienyl, pyrrolyl, oxazolyl, oxazinyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl, triazolyl, triazinyl, pyridazyl, pyrimidinyl, pyrazolyl, indolyl, indazolyl,
20 benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzoxazinyl, quinoxaliny, quinolinyl, quinazolinyl, cinnolinyl, benzothiazolyl, pyridopyrrolyl. Suitable substituents include one or more of halogen, oxo, amino, nitro, alkyl, haloalkyl, alkoxy, phenoxy and phenoxy substituted by one or more of halo, alkyl, haloalkyl or alkoxy.


25

A reduced heteroaryl group or moiety may be for example a fully or partially saturated derivative of the aforementioned heteroaryl groups. Examples of reduced

13

heteroaryl groups thus include pyrrolidinyl, tetrahydrofuryl, tetrahydrothienyl and piperidinyl.

Preferably, a compound according to the second aspect of the invention is a compound of formula (IIa):



(IIa)

or a pharmaceutically acceptable salt, ester, amide or prodrug thereof,

wherein:-

R^1 , R^4 , R^5 , R^6 , R^7 , X^1 and X^2 are as defined above for formula (Ia); and

R^8 , R^9 , R^{10} , R^{11} are each independently hydrogen, halo, hydroxy, amino, nitro, cyano,

or a group R^1 , as defined above,

or a group $R^{12}Q$ where Q is O, CO, CONH, NHCO, S, SO, SO_2 , or SO_2NH_2 and R^{12} is hydrogen or a group R^1 as defined above, with the proviso that when R^1 is $CH_2CH=CHPh$, R^8 and R^{11} are H and R^9 is OMe, R^{10} is not OMe,

25

or a group R^1R^2N where R^1 is as defined above and R^2 is hydrogen or R^1 , with the proviso that any hetero atom substituent in R^1 and/or R^2 must be separated from the nitrogen atom substituent by at least two carbon atoms (preferably saturated).

More preferably, a compound according to the first aspect of the invention comprises a compound of formula (IIa), or a pharmaceutically acceptable salt, ester, amide or prodrug thereof; wherein:

5

R^1 is a unbranched alkyl group having from 3 to 25 carbon atoms; an aryl group; an arylalkyl group wherein the alkyl moiety has from 2 to 25 carbon atoms; or an arylaryl group, wherein the arylalkyl group or the arylaryl group may be separated by a spacer, and where the spacer can be one or more of an ester, amide, O, CH_2 or a ketone;

10

R^8 is hydrogen or fluorine;

15

R^9 is lower branched or unbranched alkyl having 1 to 10 carbon atoms, preferably methyl; cyclic alkyl having 3 to 10 carbon atoms, preferably cyclopropyl; haloalkyl, preferably trifluoromethyl; or a halogen, most preferably chlorine or fluorine;

20

R^{10} is hydrogen lower branched or unbranched alkyl having 1 to 10 carbon atoms, preferably methyl; cyclic alkyl having 3 to 10 carbon atoms, preferably cyclopropyl; haloalkyl, preferably trifluoromethyl; or a halogen, most preferably chlorine or fluorine;

25

In particular, R^1 is an unbranched alkyl with 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms, a phenyl group, a phenylalkyl group wherein the alkyl is an unbranched group containing from 2 to 20 carbon atoms for example 8 to 20 carbon atoms, or a phenoxyphenyl group,

wherein the phenyl group is optionally substituted with methyl, halide or halomethyl where the halide is F, Cl, Br or I,

R^8 is hydrogen and R^9 , R^{10} and R^{11} are independently H or methyl

5

or one of R^8 , R^9 , R^{10} or R^{11} is methyl and the others of R^8 , R^9 , R^{10} and R^{11} are hydrogen,

in particular, R^8 is hydrogen and one of R^9 , R^{10} and R^{11} is methyl and the others of R^9 , R^{10} and R^{11} are hydrogen.

10

Examples of pharmaceutically acceptable salts of the compounds of formulae (I), (Ia) and (IIa) include those derived from organic acids such as methanesulphonic acid, benzenesulphonic acid and p-toluenesulphonic acid, mineral acids such as hydrochloric and sulphuric acid and the like, giving methanesulphonate, benzenesulphonate, p-toluenesulphonate, hydrochloride and sulphate, and the like, respectively or those derived from bases such as organic and inorganic bases.

15

Examples of suitable inorganic bases for the formation of salts of compounds for this invention include the hydroxides, carbonates, and bicarbonates of ammonia, lithium, sodium, calcium, potassium, aluminium, iron, magnesium, zinc and the like. Salts can also be formed with suitable organic bases. Such bases suitable for the formation of pharmaceutically acceptable base addition salts with compounds of the present invention include organic bases which are nontoxic and strong enough to form salts. Such organic bases are already well known in the art and may include amino acids such as arginine and lysine, mono-, di-, or trihydroxyalkylamines such as mono-, di-, and triethanolamine, choline, mono-, di-, and trialkylamines, such as methylamine, dimethylamine, and trimethylamine, guanidine; N-methylglucosamine; N-methylpiperazine; morpholine; ethylenediamine; N-benzylphenethylamine; tris(hydroxymethyl) aminomethane; and the like.

20

25

30




Salts may be prepared in a conventional manner using methods well known in the art. Acid addition salts of said basic compounds may be prepared by dissolving the free base compounds according to the first or second aspects of the invention in aqueous or aqueous alcohol solution or other suitable solvents containing the required acid. Where a compound of formula (I), (Ia) or (IIa) contains an acidic function a base salt of said compound may be prepared by reacting said compound with a suitable base. The acid or base salt may separate directly or can be obtained by concentrating the solution eg. by evaporation. The compounds of this invention may also exist in solvated or hydrated forms.





10

The invention also extends to prodrugs of the aforementioned compounds. A prodrug is commonly described as an inactive or protected derivative of an active ingredient or a drug which is converted to the active ingredient or drug in the body.

15 Representative compounds according to the first aspects of the invention include:

Table 1

Reference Number	Structure	Compound Name
1		6-Methyl-2-octylthio-4H-3,1-benzoxazin-4-one
2		7-Methyl-2-octylthio-4H-3,1-benzoxazin-4-one -
3		8-Methyl-2-octylthio-4H-3,1-benzoxazin-4-one

4		6-Methyl-2-phenylthio-4 <i>H</i> -3,1-benzoxazin-4-one
5		6-Methyl-2-(10-phenyldecyl)-thio-4 <i>H</i> -3,1-benzoxazin-4-one
6		6-Methyl-2-icosylthio-4 <i>H</i> -3,1-benzoxazin-4-one
7		6-Methyl-2-hexadecylthio-4 <i>H</i> -3,1-benzoxazin-4-one

Preferred compounds of the invention listed above extend to the tautomers thereof, as well as (but not limited to) pharmaceutically acceptable salts, esters, amides or prodrugs thereof or a derivative optionally with one or more lipid groups (natural or synthetic) attached.


All preferred features of the first aspect of the invention also apply to the second aspect.

A third aspect of the invention provides a process for the manufacture of any one or more of the novel compounds or derivatives according to the first or second aspects of the invention. Thus, the present invention provides a process for the preparation of a novel compound of formula (II) which process comprises:

18

Process (A) reacting a compound of formula (IV):

5



(IV)

10 with a compound of formula (V):

15




(V)

or

20 Process (B) cyclising a compound of formula (VI)

25




(VI)

wherein R¹ and R⁸-R¹¹ are as hereinbefore defined and R¹⁸ is hydrogen or C₁₋₆alkyl.

or:

Process (C) reacting a compound of formula (VII)

5



10

with a thiol of formula (VIII):




15


or:

Process (D): reacting a compound of formula (IX):

20



25 with a compound of formula (X):



or:

Process (E) converting a compound of formula (Ia) or (IIa) into a different compound of formula (Ia) or (IIa), by, for example,

5

(i) reduction of a compound of formula (Ia) or (IIa) wherein any of R^1 , R^8 , R^9 , R^{10} and R^{11} contains an alkenyl or alkynyl group or moiety, to the corresponding alkyl or alkenyl group or moiety; or

10

(ii) alkylation of a compound of formula (Ia) or (IIa) where one or more of R^8 , R^9 , R^{10} and R^{11} represents a halogen atom.

15

Process (A) may be effected by reacting a compound of formula (IV) with a chlorothiolformate of formula (V). The process is preferably carried out under basic conditions, e.g. using pyridine. An excess (more than two equivalents) of the chlorothiolformate is employed, so that the intermediate thiolcarbamate initially formed is cyclised by reaction with the excess chlorothiolformate.

20

Compounds of formula (V) for use in the process (A) may be prepared by standard methods well known in the art, e.g. by reaction of the corresponding thiol R^1SH with phosgene.

25

Process (B) may be effected by reaction of a compound (VI) wherein R^{18} is hydrogen, in the presence of a cyclisation reagent, e.g. an alkyl chloroformate, for example as described for process (A). Alternatively a compound (VI) may be cyclised by treatment with a dehydrating agent such as concentrated sulphuric acid.

Compounds of formula (VI) may be prepared by reacting a compound of formula (IV) or a corresponding ester with chlorothiolformate. It will be appreciated that when an acid of formula (IV) is employed the thiolformate should not be used in excess,

otherwise cyclisation will occur as in Process (A). However where an ester of formula (IV) is employed an excess of the thiolformate may be employed, and indeed it may be advantageous to do so.

- 5 Alternatively, compounds (VI) wherein R^{18} is an alkyl group may be prepared by reacting an ester corresponding to formula (IV) with e.g. phosgene and a base such as pyridine to afford the corresponding isocyanate, followed by treatment with an alcohol $R^{18}SH$. If desired the ester (i.e. where R^{18} is alkyl) may be hydrolysed to the corresponding acid ($R^{18}=H$) using for example lithium hydroxide in e.g. aqueous
10 tetrahydrofuran or aqueous dioxane.

It will be appreciated that process (A) also proceeds via an intermediate of formula (VI) and is hence a variant of process (B).

- 15 Process (C) may be effected by reacting a compound of formula (VII) with a thiol of formula (VIII) in the presence of a base such as triethylamine.

Process (D) may be effected by reacting a compound of formula (IX) with an alkyl iodide and potassium carbonate in a solvent such as acetone.

20

A compound of formula (IX) may be prepared by cyclisation of a compound of formula (IV), with thiophosgene. (See Krantz *et al.*, *J. Med. Chem.* 1990, 33(2):464-479).

- 25 In process (E), reduction of an alkenyl or alkynyl group may be effected for example by catalytic hydrogenation using e.g. 10% palladium on charcoal in an alcoholic solvent, such as ethanol, under 1 atmosphere of hydrogen gas.

- Alkylation according to process (E)(ii) may be effected using a Stille or other
30 palladium catalysed cross-coupling process, using e.g. tetra-alkyl tin such as

tetramethyl tin and $\text{PhCH}_2\text{Pd}(\text{PPh}_3)_2\text{Cl}$ in HMPA at elevated temperature e.g. 50-100°C. Other halides or pseudohalides e.g. triflates may be employed as starting materials.

- 5 A fourth aspect of the invention is a novel compound according to the first and/or second aspects of the invention (i.e. compounds of formulae (Ia) and (IIa)), for use in medicine. Preferred features of the first and/or second aspects of the invention also apply to the fourth aspect. Further details of the fourth aspect of the invention are set out in the text which follows.

10

The compounds of formula (Ia) and (IIa) are useful inhibitors of enzymes involved in the degradation of fats. Preferably therefore the fourth aspect of the invention provides a compound of formula (Ia) or (IIa) as defined hereinabove, or a pharmaceutically acceptable salt, ester, amide or prodrug thereof, for use in the control or treatment of obesity, or obesity-related disorders or for use in promoting non-medical weight loss.

15

- A fifth aspect of the invention relates to a compound according to the first and/or second aspects of the invention for use in the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality. This includes both *in vivo* and *in vitro* uses and other uses such as industrial uses. Such an enzyme is one which catalyses the breakdown of a substrate containing an ester functionality by the addition of water, resulting in the cleavage of a chemical bond. Such enzymes are involved in key processes in the body. Enzymes according to this invention include lipases (hydrolyse fatty acid esters), esterases (hydrolyse esters) and phosphatases (hydrolyse phosphate esters).

20

25

The enzyme is preferably a lipase. Lipases include pancreatic lipase, gastric lipase, lipoprotein lipase, lingual lipase, adipose tissue lipase, hormone sensitive lipase,

phospholipase A1, A2, B, C, D etc., hepatic lipase, and other triacyl, diacyl and monoacylglycerol lipases in the mammalian body. Many similar such lipases are also known in plants, fungi and microorganisms.

- 5 Also covered are esterase enzymes and phosphatase enzymes. Esterase enzymes include pig liver esterase, cholesteryl esterase, retinyl esterase, 1-alkyl-2-acetylglycerophosphocholine esterase, carboxylic ester hydrolases, and cholesterol esterase. Phosphatase enzymes include serine/threonine phosphatases PP1, PP2 and PP3, phosphoprotein phosphatase, myosin-light-chain phosphatase, protein
10 phosphoprotein 2C, and protein tyrosine phosphatase.

- Compounds according to the invention, for use in medicine, are primarily for use in relation to the prevention and/or treatment of a medical condition such as obesity, hyperlipaemia, hyperlipidaemia and related diseases such as hyperglycaemia (type II
15 diabetes), hypertension, cardiovascular disease, stroke, gastrointestinal disease and gastrointestinal conditions. Compounds according to the first aspect of the invention are useful in these and other conditions due to their ability to inhibit an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality (in vivo, as the enzyme naturally occurs). The invention also relates to non-medical weight
20 loss, such as cosmetic weight loss and includes improving bodily appearance in general. Throughout this text, the prevention and/or treatment of any disorder means any effect which mitigates any damage or any medical disorder, to any extent, and includes prevention and treatment themselves. The term "treatment" means any amelioration of disorder, disease, syndrome, condition, pain or a combination of two
25 or more thereof.

Preferably therefore the invention provides the use of a compound of formula (I) or (II) as defined hereinabove, or a pharmaceutically acceptable salt, ester, amide or

prodrug thereof, in the manufacture of a medicament for the control or treatment of obesity, or obesity-related disorders or for promoting non-medical weight loss.

5 Clearly, an important application of the invention is in relation to weight loss (of all kinds as described above) in humans. However, the invention applies to medical and non-medical weight loss in any animal whose metabolism of fat and fat derivatives involves an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality (*in vivo*, as the enzyme naturally occurs). Thus, the invention has veterinary application and is particularly useful in relation to medical and non-medical
10 weight loss in companion animals such as pet cats and dogs as well as in animals which provide meat for human consumption. In the case of the latter, the application of the present invention is to reduce fat content in order to provide a leaner meat product.

15 It is also believed that the compounds may be useful in reducing levels of toxins (e.g. dioxins and PCBs) stored in body fat. Without wishing to be bound by theory, it is believed that increasing the amount of undigested fat passing through the body enhances diffusion of toxins from fat stored in the body into fats in the blood, and thence into the intestine.

20 The fifth aspect of the invention has important applications. It includes test and diagnostic methods and the control and inhibition of unwanted enzymes, preferably lipases, in any process or in any product. The processes or products, which preferably involve a lipase, include: processing of agricultural commodities (e.g. oilseeds),
25 recovery and isolation of enzymes from biotechnological processes (e.g. involving lysis of microorganisms), the manufacture and extraction of crude oil (especially oil and plastics), the industrial manufacture of triglycerides or other fats, manufacture of healthcare goods which comprise surfactants, soap or detergent (e.g. bath oils, creams), the manufacturing and processing of liposomes (e.g. healthcare products,

diagnostics, gene therapy), the treatment of industrial waste (e.g. paper effluent treatment) and preventing the degradation of foodstuff which comprises a fat (e.g. chocolate processing). Thus, the invention also relates to these products and processes, e.g. a foodstuff which comprises a compound according to the first aspect of the invention, in particular foodstuffs which have a high fat content such as cakes, biscuits, pastry-products and the like and chocolate products. The preferred features of the fifth aspect of the invention, including an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality (*in vivo*, as the enzyme naturally occurs) are as discussed for the previous aspects of the invention.

A sixth aspect of the invention provides a composition comprising a novel compound according to the first or second aspect of the invention, in combination with a pharmaceutically acceptable carrier or diluent. Suitable carriers and/or diluents are well known in the art and include pharmaceutical grade starch, mannitol, lactose, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, (or other sugar), magnesium carbonate, gelatin, oil, alcohol, detergents, emulsifiers or water (preferably sterile). The composition may be a mixed preparation of a composition or may be a combined preparation for simultaneous, separate or sequential use (including administration).

The compounds according to the invention for use in the aforementioned indications may be administered by any convenient method, for example by oral (including by inhalation), parenteral, mucosal (e.g. buccal, sublingual, nasal), rectal or transdermal administration and the compositions adapted accordingly.

For oral administration, the compounds can be formulated as liquids or solids, for example solutions, syrups, suspensions or emulsions, tablets, capsules and lozenges.

A liquid formulation will generally consist of a suspension or solution of the compound or physiologically acceptable salt in a suitable aqueous or non-aqueous

liquid carrier(s) for example water, ethanol, glycerine, polyethylene glycol or an oil. The formulation may also contain a suspending agent, preservative, flavouring or colouring agent.

- 5 A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and microcrystalline cellulose.
- 10 A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, powders, granules or pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and
- 15 the dispersion or suspension then filled into a soft gelatin capsule.

Compositions for oral administration may be designed to protect the active ingredient against degradation as it passes through the alimentary tract, for example by an outer coating of the formulation on a tablet or capsule.

- 20 Typical parenteral compositions consist of a solution or suspension of the compound or physiologically acceptable salt in a sterile aqueous or non-aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and
- 25 then reconstituted with a suitable solvent just prior to administration.

- Compositions for nasal or oral administration may conveniently be formulated as aerosols, drops, gels and powders. Aerosol formulations typically comprise a solution or fine suspension of the active substance in a physiologically acceptable aqueous or
- 30 non-aqueous solvent and are usually presented in single or multidose quantities in

sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomising device. Alternatively the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal once the contents of the container have been exhausted. Where the dosage form comprises an aerosol dispenser, it will contain a pharmaceutically acceptable propellant. The aerosol dosage forms can also take the form of a pump-atomiser.

Compositions suitable for buccal or sublingual administration include tablets, lozenges and pastilles, wherein the active ingredient is formulated with a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin.

Compositions for rectal or vaginal administration are conveniently in the form of suppositories (containing a conventional suppository base such as cocoa butter), pessaries, vaginal tabs, foams or enemas.

Compositions suitable for transdermal administration include ointments, gels, patches and injections including powder injections.

Conveniently the composition is in unit dose form such as a tablet, capsule or ampoule.

The compositions of the sixth aspect of the invention are useful in the prevention and/or treatment of obesity, obesity-related disorder, other medical weight loss and non-medical related weight loss. Preferred features of this aspect of the invention are as described above for the first to fifth aspects of the invention.

A seventh aspect of the invention provides a process for the manufacture of a composition according to the sixth aspect of the invention. The manufacture can be carried out by standard techniques well known in the art and involves combining a

compound according to the first aspect of the invention and the pharmaceutically acceptable carrier or diluent. The composition may be in any form including a tablet, a liquid, a capsule, and a powder or in the form of a food product, e.g. a functional food. In the latter case the food product itself may act as the pharmaceutically acceptable carrier.

An eighth aspect of the invention provides a method for the prevention and/or treatment of obesity or an obesity-related disorder, the method comprising the administration of a compound according to the first or second aspect of the invention, preferably in combination with a pharmaceutically acceptable carrier or diluent (as per the sixth aspect of the invention). Obesity-related disorders include hyperlipemia, hyperlipideamia, hyperglycaemia, hypertension, cardiovascular disease, stroke, gastrointestinal disease and gastrointestinal conditions. The compound or composition is preferably administered to a patient in need thereof and in a quantity sufficient to prevent and/or treat the symptoms of the condition, disorder or disease. For all aspects of the invention, particularly medical ones, the administration of a compound or composition has a dosage regime which will ultimately be determined by the attending physician and will take into consideration such factors such as the compound being used, animal type, age, weight, severity of symptoms, method of administration, adverse reactions and/or other contraindications. Specific defined dosage ranges can be determined by standard design clinical trials with patient progress and recovery being fully monitored. Such trials may use an escalating dose design using a low percentage of the maximum tolerated dose in animals as the starting dose in man.

The physiologically acceptable compounds of the invention will normally be administered in a daily dosage regimen (for an adult patient) of, for example, an oral dose of between 1 mg and 2000 mg, preferably between 30 mg and 1000 mg, e.g. between 10 and 250 mg or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 50 mg, e.g. between 1 and 25 mg of the compound of the formula (I) or a physiologically acceptable salt

thereof calculated as the free base, the compound being administered 1 to 4 times per day. Suitably the compounds will be administered for a period of continuous therapy, for example for a week or more.

- 5 A ninth aspect of the invention provides a cosmetic method (non-therapeutic) for maintaining a given weight, or for cosmetic weight loss, the method comprising the administration of a compound according to the first or second aspect of the invention, preferably in combination with a pharmaceutically acceptable carrier or diluent (as per the sixth aspect of the invention). The compound or composition is preferably
10 administered to a subject in need thereof or having a requirement therefor and in a quantity sufficient to maintain a given weight or for cosmetic weight loss.

- The eighth and ninth aspects of the invention relate to methods which are applicable to humans and other animals, in particular companion animals (such as dogs and cats)
15 and other animals which provide meat for human consumption, such as cattle, pigs and sheep (all of any age).

The invention will now be described with reference to the following non-limiting examples.

Biological Test Methods and Results**Test Compounds**

5 The benzoxazinone compounds used in the following tests are identified by the reference number assigned in Table 1 hereinbefore.

Measurement of lipase activity using a quinine diimine dye colorimetric assay

10 The inhibitory activity of the selected compounds to pancreatic lipase was measured in the following assay available from Sigma Ltd (Lipase-PS™, catalog number 805-A):

Pancreatic lipase

15 1,2-dibutylin ————— > 2-monoglyceride + fatty acid

Monoglyceride lipase

2-monoglyceride ————— > glycerol + fatty acid

Glycerol kinase

20 glycerol + ATP ————— > glycerol-3-phosphate + ADP

Glycerol phosphate oxidase

glycerol-3-phosphate + O₂ ————— > dihydroxyacetone phosphate + H₂O₂

25

Peroxidase

H₂O₂ + 4-AAP + TOOS ————— > quinine diimine dye + 4H₂O

The glycerol released from the action of pancreatic and monoglyceride lipase was oxidised to release H_2O_2 . The peroxidase reaction step then produces a quinine dye which is pink in colour and absorbs light at a wavelength of 550 nm.

5 Inhibitor

Individual test compounds were dissolved in DMSO (dimethyl sulphoxide) at 10 mM. DMSO was used to avoid any problems with compounds being water-insoluble.

10 For individual compounds, the IC_{50} (concentration at which lipase activity is inhibited to one half of the maximum) was calculated by measuring the inhibitory activity from log-dose response curves using a range of inhibitor concentrations.

Results

15 Compounds 1, 2, 3, 5, 6 and 7 were assayed in the quinine diimine dye colorimetric assay which provides a rapid method to measure lipase inhibitory activity. None of the compounds tested interfered with the colorimetric reaction, i.e. they did not give false positive results.

20 A range of inhibitory activities for the tested compounds was observed, indicating that these compounds are inhibitors of human pancreatic lipase. Compounds 1, 2, 3, 5, 6 and 7 all had an IC_{50} of <100 nM.

Measurement of lipase enzyme activity using a NaOH titration method

25

The inhibitory activity of the selected compounds to pancreatic lipase was measured in the assay described in Pasquier *et al*; 1996, Vol 7, *Nutritional Biochemistry*, 293-302.

Log dose/response curves were constructed using a range of inhibitor concentrations.

Results


5 Selected benzoxazinone compounds were tested in the NaOH titration assay. In this assay, the activity of porcine pancreatic lipase in a system containing lipid micelles is recorded. These conditions are therefore similar to those encountered in the gastrointestinal tract.

10 A range of inhibitory activities were observed for the tested benzoxazinone compounds in this assay, indicating that these compounds are inhibitors of porcine pancreatic lipase. Compounds 4 and 5 had an IC_{50} of less than 1 microMolar.

15 The results demonstrate that a number of selected benzoxazinones are inhibitors of fat digestion and that these compounds may be particularly suitable for the treatment of obesity.

Synthesis of novel compounds according to the inventionExample 1

5

Preparation of 2-octylthio-6-methyl-4H-3,1-benzoxazin-4-one

10 (a) 1-Octanethiol (5 ml, 28 mmol) and trioctylphosphine oxide (22 mg, 0.056 mmol) were heated to 80°C. Phosgene solution (20% in PhMe, 14.4 ml, 30 mmol) was added portionwise over the course of 1 hour, then the reaction was maintained at 80°C for a further 1 hour. After allowing to cool to room temperature, hydrogen chloride and excess phosgene were removed overnight under a gentle stream of nitrogen, the vented gas being passed through a sodium hydroxide scrubber. The crude octyl chlorothioformate was used directly in the next step.

15

(b) 2-Amino-5-methylbenzoic acid (1.51 g, 10 mmol) was dissolved in pyridine (10 ml), and to this was added the crude octyl chlorothioformate (28 mmol, assuming 100% from the first step) as a solution in toluene. After 2h, the reaction was diluted with ethyl acetate and washed three times with 1M aqueous HCl, then saturated aqueous sodium bicarbonate, water and brine. The organic phase was dried (MgSO_4) and concentrated *in vacuo*. Crystallisation from hexane gave the title compound (155 mg, 5%): δ_{H} (400 MHz, CDCl_3) 0.91 (3H, t, J 7.0, Me), 1.30-1.34 (8H, m, $4 \times \text{CH}_2$), 1.44-1.50 (2H, m, $\text{SCH}_2\text{CH}_2\text{CH}_2$), 1.79 (2H, qn, J 7.4, SCH_2CH_2), 2.46 (3H, s, ArMe),


20

25

3.16 (2H, t, J 7.3, SCH₂), 7.38 (1H, d, J 8.2, ArH), 7.58 (1H, dd, J 8.2, 1.8, ArH), 7.93 (1H, s, ArH); m/z (ES⁺) 306 (MH⁺).

5 Example 2

Preparation of 2-octylthio-7-methyl-4H-3,1-benzoxazin-4-one



10

1-Octanethiol (0.71 ml, 4.1 mmol) was dissolved in THF (10 ml). To this solution was added a solution of phosgene (20% in PhMe, 3.5 ml, 7.4 mmol). After 2.5 h the reaction vessel was purged with nitrogen to remove excess phosgene and hydrogen chloride, the vented gas being passed through a scrubber containing dilute aqueous sodium hydroxide. The crude octyl chlorothioformate solution was used directly.

15

2-Amino-4-methylbenzoic acid (151 mg, 1 mmol) was dissolved in pyridine (0.5 ml) and DCM (5 ml). To this was added one quarter of the crude octyl chlorothioformate solution (1 mmol, assuming 100% from the first step). After 24h, the reaction was diluted with ether and washed with 1M aqueous HCl and brine. The organic phase was dried (MgSO₄) and concentrated *in vacuo*. The residue was purified by flash chromatography (EtOAc/hexane gradient) to give a solid which was triturated with acetonitrile to afford the title compound (43 mg, 14%): δ_H (400 MHz, CDCl₃) 0.82 (3H, t, J 6.7, Me), 1.21-1.24 (8H, m, 4 \times CH₂), 1.37-1.41 (2H, m, SCH₂CH₂CH₂), 1.68-1.72 (2H, m, SCH₂CH₂), 2.40 (3H, s, ArMe), 3.08 (2H, t, J


20

35

7.4, SCH₂), 7.16 (1H, d, *J* 8.0, ArH), 7.19 (1H, d, *J* 1.4, ArH), 7.93 (1H, d, *J* 8.0, ArH); *m/z* (ES⁺) 306 (MH⁺).

Example 4

5

Preparation of 2-phenylthio-6-methyl-4*H*-3,1-benzoxazin-4-one

- 10 2-Amino-5-methylbenzoic acid methyl ester (122 mg, 0.79 mmol) and triethylamine (0.28 ml, 1.96 mmol) were dissolved in THF (10 ml). A 20% solution of phosgene in toluene (0.74 ml, 1.6 mmol) was added, causing immediate formation of a white precipitate. After 1 h, excess phosgene was purged with a stream of nitrogen, the vented gas being passed through a base scrubber. Thiophenol (81 μ l, 0.79 mmol)
- 15 was added to this crude isocyanate solution, which was then stirred for 1 h. The mixture was filtered to remove triethylamine hydrochloride, the solid being washed with ether. After concentration of the filtrate, the residue was purified by flash chromatography (5% to 10% EtOAc/petrol) to give 5-methyl-2-phenylsulfanylcabonylaminobenzoic acid, methyl ester: *m/z* (ES⁻) 300 (M-H).

20

A portion of this material (82 mg, 0.27 mmol) was cyclised by dissolving it in concentrated sulfuric acid (5 ml). After 2.5 h, the mixture was poured carefully onto a mixture of ice and aqueous sodium bicarbonate, with further portions of solid sodium carbonate being added periodically to avoid the mixture becoming acidic.

- 5 The resulting mixture was extracted with ethyl acetate, the organic phase then being dried (MgSO_4) and concentrated to afford the title compound (64 mg, 0.24 mmol, 87%) as a yellow solid, which did not require further purification: δ_{H} (400 MHz, CDCl_3) 2.35 (3H, s, ArMe), 7.20 (1H, d, J 8.5, ArH), 7.39-7.46 (4H, m, ArH), 7.58-7.60 (2H, m, ArH), 7.82 (1H, s, ArH); m/z (ES^+) 270.2 (MH^+).


10

- The foregoing description details specific compounds, compositions, methods and uses which can be employed to practice the present invention. However, those skilled in the art will know how to use alternative reliable methods for aiming at
- 15 alternative embodiments of the invention which are herein encompassed.

Claims

1. Use of a compound of formula (I):

5



(I)

- 10 or a pharmaceutically acceptable salt, ester, amide or prodrug thereof;
in the manufacture of a medicament for the treatment of a condition which requires
the inhibition of an enzyme whose preferred mode of action is to catalyse the
hydrolysis of an ester functionality
wherein in formula (I):

15

A is an optionally substituted 6-membered aromatic or heteroaromatic ring; and


- R¹ is a branched or unbranched alkyl (optionally interrupted by one or more oxygen
atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl,
20 arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced
heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing
groups, wherein the substituents are one or more independently of halogen, alkyl,
halosubstituted alkyl, aryl, arylalkyl, heteroaryl, reduced heteroaryl, reduced
heteroarylalkyl, arylalkoxy, cyano, nitro, -C(O)R⁴, -CO₂R⁵, -SOR⁴, -SO₂R⁴, -NR⁶R⁷, -
25 OR⁶, -SR⁶, -C(O)CX¹X²NR⁶R⁷, -C(O)N(OH)R⁶, -C(O)NR⁵R⁴, -NR⁶C(O)R⁴, -
CR⁶(NH₂)CO₂R⁶, -NHCX¹X²CO₂R⁶, -N(OH)C(O)NR⁶R⁷, -N(OH)C(O)R⁴, -
NHC(O)NR⁶R⁷, -C(O)NHNHNR⁶R⁷, -C(O)N(OR⁵)R⁶, or a lipid or steroid (natural or
synthetic) with the proviso that any hetero atom substituent in R¹ must be separated
from the exocyclic sulphur atom by at least two carbon atoms (preferably saturated);

30

and where:-

- 5 R^4 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, reduced heteroaryl, reduced heteroarylalkyl, $-OR^6$, $-NHCX^1X^2CO_2R^6$ or $-NR^6R^7$;
- R^5 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl heteroaryl, heteroarylalkyl, reduced heteroaryl or reduced heteroarylalkyl; and
- 10 R^6 and R^7 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, reduced heteroaryl, reduced heteroarylalkyl or $-(CH_2)_n(OR^5)_m$ wherein n is 1 to 12, preferably 2 to 10, wherein m is 1-3 and R^5 is most preferably C_2-C_{10} alkyl; and
- 15 X^1 and X^2 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, reduced heteroaryl or reduced heteroarylalkyl.

- 20 2. A compound of formula (Ia):



or a pharmaceutically acceptable salt, ester, amide or prodrug thereof;
wherein in formula (Ia):

- 30 A is an optionally substituted 6-membered aromatic or heteroaromatic ring; and

R^1 is a branched C_{4-50} alkyl or unbranched C_{3-25} alkyl (with the alkyl group optionally interrupted by one or more oxygen atoms), C_{2-25} alkenyl, C_{2-25} alkynyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkenyl, aryl, aryl C_{2-25} alkyl, reduced aryl C_{1-25} alkyl, aryl C_{2-25} alkenyl, heteroaryl, heteroaryl C_{2-25} alkyl, heteroaryl C_{2-25} alkenyl, reduced aryl, reduced heteroaryl, reduced heteroaryl C_{2-25} alkyl or a substituted derivative of any of the foregoing groups, wherein the substituents are one or more independently of halogen, alkyl, halosubstituted alkyl, aryl, arylalkyl, heteroaryl, reduced heteroaryl, reduced heteroarylalkyl, arylalkoxy, cyano, nitro, $-C(O)R^4$, $-CO_2R^5$, $-SOR^4$, $-SO_2R^4$, $-NR^6R^7$, $-OR^6$, $-SR^6$, $-C(O)CX^1X^2NR^6R^7$, $-C(O)N(OH)R^6$, $-C(O)NR^5R^4$, $-NR^6C(O)R^4$, $-CR^6(NH_2)CO_2R^6$, $-NHCX^1X^2CO_2R^6$, $-N(OH)C(O)NR^6R^7$, $-N(OH)C(O)R^4$, $-NHC(O)NR^6R^7$, $-C(O)NHNHNR^6R^7$, $-C(O)N(OR^5)R^6$, or a lipid or steroid (natural or synthetic) with the proviso that any hetero atom substituent in R^1 must be separated from the exocyclic sulphur atom by at least two carbon atoms (preferably saturated);

15

and where:-

R^4 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, reduced heteroaryl, reduced heteroarylalkyl, $-OR^6$, $-NHCX^1X^2CO_2R^6$ or $-NR^6R^7$;

20

R^5 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, reduced heteroaryl or reduced heteroarylalkyl; and

25

R^6 and R^7 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, reduced heteroaryl, reduced heteroarylalkyl or $-(CH_2)_n(OR^5)_m$ wherein n is 1 to 12, wherein m is 1-3; and


40

X^1 and X^2 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, reduced heteroaryl or reduced heteroarylalkyl

5 with the proviso that when A is phenyl disubstituted at the 6 and 7 positions with methoxy groups, R^1 is not $CH_2CH=CHPh$.

3. A compound according to claim 2 of formula (IIa):

10



15

or a pharmaceutically acceptable salt, ester, amide or prodrug thereof,

wherein:-

20 $R^1, R^4, R^5, R^6, R^7, X^1$ and X^2 are as defined above for formula (Ia); and

R^8, R^9, R^{10}, R^{11} are each independently hydrogen, halo, hydroxy, amino, nitro, cyano,

or a group R^1 , as defined above,

25

or a group $R^{12}Q$ where Q is O, CO, CONH, NHCO, S, SO, SO₂, or SO₂NH₂ and R^{12} is hydrogen or a group R^1 as defined above, with the proviso that when R^1 is $CH_2CH=CHPh$, R^8 and R^{11} are H and R^9 is OMe, R^{10} is not OMe,

or a group R^1R^2N where R^1 is as defined above and R^2 is hydrogen or R^1 , with the proviso that any hetero atom substituent in R^1 and/or R^2 must be separated from the nitrogen atom substituent by at least two carbon atoms (preferably saturated).

- 5 4. A compound according to claim 3, wherein R^1 is a unbranched alkyl group having from 3 to 25 carbon atoms; an aryl group; an arylalkyl group wherein the alkyl moiety has from 2 to 25 carbon atoms; or an arylaryl group, wherein the arylalkyl group or the arylaryl group may be separated by a spacer, and where the spacer can be one or more of an ester, amide, O, CH_2 or a ketone;

10

R^8 is hydrogen or fluorine;

R^9 is lower branched or unbranched alkyl having 1 to 10 carbon atoms; cyclic alkyl having 3 to 10 carbon atoms; haloalkyl; or a halogen;

15

R^{10} is hydrogen lower branched or unbranched alkyl having 1 to 10 carbon atoms; cyclic alkyl having 3 to 10 carbon atoms; haloalkyl; or a halogen; and

20

R^{11} is hydrogen lower branched or unbranched alkyl having 1 to 10 carbon atoms or a halogen.

5. A compound as claimed in claims 3 or 4, or a pharmaceutically acceptable salt, ester, amide or prodrug thereof wherein
 R^1 is an unbranched alkyl with 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon
25 atoms, a phenyl group, a phenylalkyl group wherein the alkyl is an unbranched group containing from 2 to 20 carbon atoms, or a phenoxyphenyl group,
wherein the phenyl group is optionally substituted with methyl, halide or halomethyl
where the halide is F, Cl, Br or I,

30

R^8 is hydrogen,

and R^9 , R^{10} and R^{11} are independently H or methyl


6. A novel compound of formula IIa as defined in any one of claims 3 to 5 selected from

- 6-Methyl-2-octylthio-4*H*-3,1-benzoxazin-4-one;
- 7-Methyl-2-octylthio-4*H*-3,1-benzoxazin-4-one;
- 8-Methyl-2-octylthio-4*H*-3,1-benzoxazin-4-one;
- 6-Methyl-2-phenylthio-4*H*-3,1-benzoxazin-4-one
- 6-Methyl-2-(10-phenyldecyl)thio-4*H*-3,1-benzoxazin-4-one
- 6-Methyl-2-icosylthio-4*H*-3,1-benzoxazin-4-one
- 6-Methyl-2-hexadecylthio-4*H*-3,1-benzoxazin-4-one

or a pharmaceutical acceptable salt, ester, amide or prodrug thereof.

7. A process for the preparation of a novel compound of formula (Ia) or (IIa) which process comprises:

Process (A): reacting a compound of formula (IV):



with a compound of formula (V):

5




(V)

10

or

Process (B) cyclising a compound of formula (VI)

15



(VI)


20

wherein R¹ and R⁸-R¹¹ are as hereinbefore defined and R¹⁸ is hydrogen or C₁₋₆alkyl.

or:


25

Process (C) reacting a compound of formula (VII)




(VII)

with a thiol of formula (VIII):




or:

Process (D): reacting a compound of formula (IX):



15

with a compound of formula (X):



20 or:

Process (E) converting a compound of formula (Ia) or (IIa) into a different compound of formula (Ia) or (IIa), by, for example,

25 (i) reduction of a compound of formula (Ia) or (IIa) wherein any of R^1 , R^8 , R^9 , R^{10} and R^{11} contains an alkenyl or alkynyl group or moiety, to the corresponding alkyl or alkenyl group or moiety; or

(ii) alkylation of a compound of formula (Ia) or (IIa) where one or more of R^8 , R^9 , R^{10} and R^{11} represents a halogen atom.

8. A compound according to claims 2 to 6 for use in medicine.

5

9. A compound as claimed in claim 8 for the treatment of a condition which requires the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality.

10. A compound according to claim 9 wherein said condition is selected from obesity, hyperlipaemia, hyperlipidaemia, hyperglycaemia (type II diabetes), hypertension, cardiovascular disease, stroke, gastrointestinal disease and gastrointestinal conditions.

11. A compound according to any of claims 2 to 6 for use in reducing levels of toxins in body fat.

12. A compound according to any one of claims 2 to 11 for administration to humans.

20

13. A compound according to any one of claims 2 to 11 for administration to animals.

14. A pharmaceutical composition comprising a novel compound of formula (Ia) or (IIa) as defined in any one of claims 2 to 6 or a pharmaceutically acceptable salt, ester, amide or pro-drug thereof, in combination with a pharmaceutically acceptable carrier or diluent.

25

15. A food product comprising a compound of formula (Ia) or (IIa) as defined in any one of claims 2 to 6 or a pharmaceutically acceptable salt, ester, amide or pro-drug

30

thereof.

16. A method for the prevention or treatment of obesity or an obesity related disorder, the method comprising administering a compound, as defined in any one of
5 claims 2 to 6, or a composition as claimed in claim 14 or claim 15 to a patient.
17. A compound, as defined in any one of claims 2 to 6, for use in the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality.
10
18. A compound as claimed in any one of claims 2 to 6 for use in the inhibition of an esterase, a phosphoesterase or a lipase enzyme.
19. Use of a compound as defined in any of claims 2 to 6 or a pharmaceutically acceptable salt, ester, amide or prodrug thereof to reduce fat content of animals which
15 provide meat for human consumption.
20. A cosmetic method for maintaining a given weight, or for cosmetic weight loss, the method comprising the administration of a compound as defined in any of
20 claims 2 to 6.
21. A compound comprising formula (Ia) hereinbefore described with reference to one or more of the examples.
22. A process for obtaining a compound comprising formula (Ia) hereinbefore described with reference to one or more of the examples.
25
23. The use of a compound comprising formula (Ia) or (IIa) in the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester
30 functionality hereinbefore described with reference to one or more of the examples.

24. Use of a compound as claimed in any one of claims 1 to 6 in the control and inhibition of unwanted enzymes in a process or product.
- 5 25. Use of a compound as claimed in any one of claims 1 to 6 in the manufacture of healthcare goods comprising surfactants, soap or detergents.
26. Use of a compound as claimed in any one of claims 1 to 6 in preventing the degradation of foodstuff which comprises a fat.

INTERNATIONAL SEARCH REPORT

 International Application No
 PCT/GB 01/00171

 A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07D265/24 A61P3/04 A61K31/536

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,Y	WO 00 40247 A (DUNK CHRISTOPHER ROBERT ;HODSON HAROLD FRANCIS (GB); MITCHELL TIMO) 13 July 2000 (2000-07-13) cited in the application claims	1-24
P,Y	WO 00 40569 A (DUNK CHRISTOPHER ROBERT ;HODSON HAROLD FRANCIS (GB); MITCHELL TIMO) 13 July 2000 (2000-07-13) cited in the application claims	1-24
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

3 April 2001

Date of mailing of the international search report

24 APR 2001

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

Johnson, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 01/00171

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KRANTZ, ALLEN ET AL: "Design and synthesis of 4H-3,1-benzoxazin-4-ones as potent alternate substrate inhibitors of human leukocyte elastase" J. MED. CHEM., vol. 33, no. 2, 1990, pages 464-479, XP000929225 cited in the application Table II, examples 52-72	1-9, 12-14, 17,18, 21-24
X	ROBINSON, VALERIE ET AL: "13-C nuclear magnetic resonance and reactivity of 4H-3,1-benzoxazin-4-ones" CAN. J. CHEM., vol. 66, no. 3, 1988, pages 416-419, XP000985354 compounds 5,6,7,22	1-6,8,9, 12-14, 17,18, 21,23,24

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 01/00171

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 16 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 1-3,5,6,14,15,19 (part)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-3,5,6,14,15,19 (part)

Present claims 1-3, 5, 6, 14, 15 and 19 relate not only to clearly defined compounds and their uses, but also to compounds defined by reference to a desirable characteristic or property, namely prodrugs. The claims cover all compounds having this characteristic or property, whereas the application provides no support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds of formula (I) and their pharmaceutically acceptable salts, esters and amides.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 01/00171

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0040247 A	13-07-2000	AU 1884600 A	24-07-2000
WO 0040569 A	13-07-2000	AU 1884500 A	24-07-2000